Burning Rock Biotech Limited Announces Expected Delisting of American Depositary Shares

Core Viewpoint - Burning Rock Biotech Limited intends to delist its American Depositary Shares (ADSs) from the London Stock Exchange (LSE) due to low trading volume and associated costs, with the delisting expected to take effect around September 18, 2024 [1]. Group 1 - The company will submit requests to the LSE for cancellation of trading admission of its ADSs and to the UK Financial Conduct Authority for cancellation of the ADSs listing on the Official List [1]. - The decision for delisting is driven by sustained low trading volume and liquidity in the ADSs on the LSE [1]. - Following the delisting, the ADSs will continue to be traded on the Nasdaq Global Market [2]. Group 2 - Burning Rock Biotech Limited focuses on next generation sequencing (NGS) technology in precision oncology, offering NGS-based therapy selection testing for late-stage cancer patients and NGS-based cancer early detection [3]. - The company's early detection technology has progressed from proof-of-concept research and development into the clinical validation stage [3].